Additional data from Phase 2b/3 Selection trial evaluating filgotinib in 1,348 biologic-naïve or biologic-experienced for the treatment of moderate to severe active ulcerative colitis (UC) patients, demonstrated sustained efficacy and safety. Results were presented at the 2020 United European Gastroenterology Week Virtual Meeting.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,